2012 ACR/ARHP Annual Meeting

November 9-14, 2012. Washington, DC.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2648

Randomized Placebo-Controlled Trial of Local Steroid Injection for Moderately Severe Carpal Tunnel Syndrome
Abstract Number: 2620

Randomized, Double-Blind, Placebo-Controlled Studies of P140 Peptide in Mannitol (Lupuzor) and Trehalose (Forigerimod) in Patients with SLE
Abstract Number: 2655

Rapid and Effective Response to Immunosuppression in Treating Macrophage Activation Syndrome Associated with a Heterozygous Dominant Negative Mutation in RAB27a Leading to Decreased Cytolytic Activity
Abstract Number: 558

Rapid Improvements in Patient Reported Outcomes with Certolizumab Pegol in Patients with Axial Spondyloarthritis, Including Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis: 24 Week Results of a Phase 3 Double Blind Randomized Placebo-Controlled Study
Abstract Number: 2642

Rate and Predictors of Work Disability in Fibromyalgia
Abstract Number: 2093

Rates of Opportunistic Infections Among Rheumatoid Arthritis Patients Switching Biologic Therapy
Abstract Number: 1215

Rates of Orthopaedic Interventions for Rheumatoid Arthritis Have Changed Over the Last 25 Years. A Report From Two UK Inception Cohorts Reflecting Treatment Changes From Sequential DMARD Monotherapy to Anti-TNF Agents (1986-2011)
Abstract Number: 2094

Reactivation of Hepatitis B Virus in Autoimmune Disease Patients Receiving Immunosuppressive Agents
Abstract Number: 2441

Readability and Suitability Assessment of Patient Education Materials in Rheumatic Diseases
Abstract Number: 1405

Real World Experience Comparing Multiplex Immunobead Assay versus Immunoflorescence Assay for Anti-Nuclear Antibody Detection At a University Hospital
Abstract Number: 2246

Real World Experience with Belimumab in the Management of Systemic Lupus Erythematosus (SLE): A Single Center, Observational, Post-Marketing Study
Abstract Number: 496

Real-World Effectiveness of Infliximab in Improving Routine Assessment of Patient Index Data 3 Outcomes: The Canadian Experience
Abstract Number: 460

Real-World Efficacy and Safety of Abatacept Treatment for Rheumatoid Arthritis: 12-Month Interim Analysis of the Action Study
Abstract Number: 1159

Reasons and Predictors of Methotrexate Discontinuation in Children with JIA: Results From the Childhood Arthritis Prospective Study (CAPS)
Abstract Number: 34

Rebamipide Attenuates Pain Severity and Cartilage Degeneration in a Rat Model of Osteoarthritis by Downregulating Oxidative Damage and Catabolic Activity in Chondrocytes

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].